AM-919.

AM-919 is a tricyclic synthetic cannabinoid designed as a hybrid between classical dibenzopyran-type cannabinoids and non-classical cannabinoids of the CP-55,940 type: on a hexahydrobenzo[c]chromene skeleton bearing a 1,1-dimethylheptyl chain at C-3 and a hydroxymethyl at C-9 is added a 3-hydroxypropyl chain at the 6-beta position, which reproduces the so-called southern aliphatic hydroxyl of CP-55,940. The only data found are [3H]CP-55940 displacement measurements (ChEMBL, from Drake 1998): Ki of 2.2 nM at the CB1 receptor (rat forebrain) and 3.4 nM at the CB2 receptor (mouse spleen), i.e. a very high affinity at both receptors, without marked selectivity. Within the series, Tius et al. (1995) had concluded that the beta orientation of the southern hydroxyalkyl chain is decisive, whereas its length, up to three carbons, matters little. Beyond these binding assays, nothing has been established: intrinsic efficacy was not found, in vivo effects are not described in the sources consulted, and human data are entirely lacking.

Source

An exclusively synthetic molecule. It exists neither in cannabis nor in any living organism: it was created in an academic laboratory as a chemical probe, to explore the role of the southern aliphatic hydroxyl in binding to cannabinoid receptors (Drake 1998). It is cited online: a forum-crawling robot, active from 14 November 2017 to 31 May 2019, picked it up among 1,103 synthetic cannabinoids, without it being on the UNODC list (13 June 2019) or in the EMCDDA database (1 April 2019) (Zangani 2020). No seizure and no use in a consumer product is reported in the sources consulted.

No known biosynthetic pathway: AM-919 comes from no living organism. It is obtained by chemical synthesis and described here only by its class, that of the hybrids between classical and non-classical cannabinoids with a hydroxyalkyl chain at the 6-beta position.

European Union

No Union-wide control measure targets AM-919: it is not among the substances named in the annex of Framework Decision 2004/757/JHA as supplemented by Directives (EU) 2017/2103, 2019/369, 2020/1687, 2021/802, 2022/1326 and 2025/2062, nor in Schedule II of the 1971 Convention (Green List of the International Narcotics Control Board, 35th edition, 2024). The survey by Zangani et al. (2020), which compares the EMCDDA database as of 1 April 2019 and the UNODC list as of 13 June 2019 with forum mentions, places it outside both directories. Several Member States nevertheless apply generic provisions or analogue laws that may target it, and this status may change.

France

AM-919 is named nowhere in the consolidated list of ANSM (updated 16 February 2026). It falls, subject to a reading reservation, under the generic clause of annex IV stemming from the decisions of 22 May and 3 June 2024 (classification applicable from 3 June 2024): “any substance derived from the benzo[c]chromene nucleus”, non-, partially or fully hydrogenated on ring A, substituted notably “at position 1 by a hydroxyl function”, “at position 3 by an alkyl, alkenyl, alkynyl… chain”, “at position 6 by one or two alkyl groups” and “at position 9 by a ketone, alkyl, hydroxyalkyl or alkoxy function”, excluding cannabinol, cannabinolic acid, THCV and THCVA below 0.3 % and THCA below the legal content. AM-919 bears a hydroxyl at position 1, a 1,1-dimethylheptyl chain at position 3, a hydroxymethyl at position 9 and, at position 6, a methyl and a 3-hydroxypropyl chain; the reservation is that the text, which expressly allows substituents on the chain at position 3, does not say whether a hydroxylated alkyl group is an “alkyl group” at position 6. This is a reading of the text and not a nominative decision of ANSM. The entry covering tetrahydrocannabinols, their esters, ethers and salts (annex III since the decision of 6 February 2026) does not concern it, the molecule being a substituted hexahydrocannabinol.

Sources: EUR-Lex, UNODC, CND, ANSM, IUPHAR/BPS, ChEBI, EUDA. Our method.

Family

Synthetic CB receptor agonist › Research ligand or medicine

Class

classical

Verification

Classification, sources and binding values checked on 20 October 2026; text read against its sources and Wikipedia.

Wikipedia (English)

AM-919 (new tab)

Article paired by the molecule's structure (InChIKey), revision read on 19 October 2026. Read as a second opinion, never cited as a source.

1. 1Drake et al., Journal of Medicinal Chemistry, 1998: classical/non-classical hybrids with a functionalised southern chain, C-6β methyl, ethyl and propyl analogues (AM-919 = 6β-(3-hydroxypropyl)) (new tab)PMID 9733485
2. 2Tius et al., Life Sciences, 1995: classical/non-classical hybrids, stereochemical requirements of the southern hydroxyalkyl chain (new tab)PMID 7776825
3. 3ChEMBL, compound CHEMBL121118 (AM-919): CB1 Ki 2.2 nM (rat forebrain synaptosomal membranes) and CB2 Ki 3.4 nM (mouse spleen), [3H]CP-55940 displacement, document CHEMBL1131094 = J Med Chem 1998;41:3596 (new tab)
4. 4Zangani et al., Current Neuropharmacology, 2020: AM-919 picked up by a forum web crawler (14 November 2017 - 31 May 2019), absent from the UNODC (13 June 2019) and EMCDDA (1 April 2019) lists (new tab)PMID 32116194
5. 5ANSM, consolidated list of substances classified as narcotics, updated 16 February 2026, annex IV: « any substance derived from the benzo[c]chromene nucleus » clause (decisions of 22 May and 3 June 2024) (new tab)
6. 6ANSM, ANSM adds new cannabinoids to the narcotics list, in force on 3 June 2024 (new tab)
7. 7INCB, Green List of psychotropic substances under international control, 35th edition, 2024 (Schedule II: AM-919 absent) (new tab)
8. 8PubChem, compound CID 10741414 (AM-919): identifiers, structure, CAS 164228-46-0 (new tab)

SMILES

CCCCCCC(C)(C)C1=CC2=C([C@@H]3C[C@@H](CC[C@H]3[C@](O2)(C)CCCO)CO)C(=C1)O

Machine-readable entry (JSON)

LLM ingestion format: a structured superset of the entry (identifiers, binding, versioned legal status). Full corpus.